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Prevalence of HIV, Hepatitis B and C, and Co-infections 
Among Male Injection Drug Users in Delhi, India 
RESEARCH
UPDATE
JUNE 2013
India has a large injection drug user (IDU) popula-
tion estimated at about 177,000 nationally with an 
HIV prevalence of 7.2 percent1,2. Historically, the 
presence of IDU populations and associated HIV in-
fection was concentrated in the northeastern states 
of the country. Recent evidence documents IDU pop-
ulations in other parts of the country. Delhi has an 
estimated 17,000 IDUs and the second highest HIV 
prevalence in India at 18.3 percent3. The probability 
of becoming infected with HIV after using an infect-
ed syringe ranges from 0.34 percent to 1.4 percent. 
By comparison, the risk for hepatitis C (HCV) ranges 
from 1.5 percent to 5 percent4. Several studies have 
documented high prevalence of HIV-HCV co-infection 
among IDUs in the high HIV prevalence states of 
India5–6 but there is little evidence from the low HIV 
prevalence states in the country. 
The Population Council, in collaboration with the Sa-
hara Center for Residential Care and Rehabilitation 
(SAHARA) and the Arise—Enhancing HIV Prevention 
Programs for At-Risk Populations, is implementing a 
project to avert HIV infections among IDUs and their 
sexual partners in Delhi. As part of the evaluation 
of this project, we conducted an assessment of the 
prevalence of HIV, hepatitis B (HBV) and HCV infec-
tion in a cohort of male IDUs in Delhi. 
Methods
Participants were recruited from May to October 
2011 through targeted outreach, peer-referral 
and as walk-in clients. Recruitment criteria includ-
ed having injected drugs at least once in the last 
three months, aged 18 years or older, residing in or 
around Delhi, willing to participate in the study, and 
provide written consent. The IDUs were registered at 
the five drop-in centers (DICs) operated by SAHARA 
in central, east, northeast and northwest districts 
of Delhi. All participants were offered baseline HIV,  
HBV, and HCV testing prior to the initiation of the HIV 
prevention intervention. Trained research inter-
viewers administered close-ended questionnaire in 
Hindi to collect data on socio-demographic char-
acteristics, injecting practices, sexual behaviours, 
knowledge of HIV, and utilization of harm reduction 
services.
This material was produced under Arise—Enhancing HIV Prevention for At-Risk Populations. Arise implements innovative HIV prevention initiatives for 
vulnerable communities, with a focus on determining cost-effectiveness through rigorous evaluations.
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Laboratory testing
HIV sero-status at baseline was determined using 
rapid tests as per National AIDS Control Organi-
zation (NACO) guidelines. HIV-negative status was 
based on a single highly sensitive rapid test and a 
positive result on two additional confirmatory rapid 
tests. At the follow-up visit, all HIV-negative IDUs 
were retested using a fourth generation Antigen-An-
tibody test followed by a confirmatory Western Blot 
Assay. 
For the detection of HBV infection, a serum spec-
imen was tested for HBV surface antigen. HCV 
antibodies were detected using CMIA/Electroche-
miluminescence test. Active infection of HCV was 
confirmed using an RNA PCR test. 
Study Population
A total of 3,792 IDUs were recruited into the study. 
Of those, 2,292 male IDUs who had completed 
both the baseline and follow-up assessments, and 
for whom confirmatory results were available, were 
included in the analysis to calculate the prevalence 
rates of HIV, HBV, and HCV infection. Median age 
was 29 years, 48 percent were illiterate, 53 percent 
were never married, and 62 percent belonged to 
the Hindu religion. They came mostly from three 
adjacent states of Delhi (44 percent). Although, the 
majority were home-based (44 percent) many were 
also living on the streets (39 percent). 
Key Findings
Low HIV, HBV, and HVC knowledge  
among male IDUs
Almost two-thirds (63 percent) of male IDUs did not 
have comprehensive knowledge on HIV transmission 
despite the fact that 54 percent had been injecting 
for two to five years. HIV knowledge was assessed 
using a six-item index comprising correct knowledge 
of the participant that HIV transmission can be pre-
vented by (i) correct and consistent use of condoms 
for sex; (ii) having a monogamous uninfected sexual 
partner; (iii) that sharing needles/syringes increas-
es the risk of HIV transmission; that HIV infection 
cannot spread (iv) from mosquito bites or (v) from 
sharing food; and (vi) healthy-looking people can be 
infected with HIV. Further, only 8.6 percent (n=198) 
had heard of HBV and 2.9 percent (n=66) had heard 
of HCV. 
High-risk injection behaviors  
were commonly reported 
Over half (52 percent) of male IDUs reported at least 
one risky injection practice in the last month prior to 
the survey. Sharing injection-related equipment (32 
percent) and drawing from a common container (48 
percent) were most frequent. Injecting with a used 
needle was less frequently reported (26 percent). 
Around 45 percent reported use of needle/syringe 
exchange services in the previous month. 
High prevalence of HIV, HCV, and  
co-infection
Among those who completed the follow-up assess-
ment, HIV prevalence was 26.0 percent (n=595) 
and HCV prevalence was 53.7 percent (n=1,230). 
About a fifth (19.6 percent; n=449) of IDUs had both 
HIV and HCV (Figure 1). HCV prevalence reported 
here denotes active HCV infection. 
Figure 1  HIV and active HCV prevalence among 
                male IDUs, Delhi (n=2,292)
HCV was common among the HIV-positive IDUs; 
75.5 percent of HIV-positive IDUs tested positive for 
HCV. Among HCV-infected IDUs, 36.5 percent were 
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Low prevalence of HBV and  
co-infection of HIV
Overall, 9.7 percent (n=223) of male IDUs were in-
fected with HBV and 4 percent (n=91) of male IDUs 
had both HBV and HCV. More than a tenth (12.8 
percent; n=77) of HIV positive IDUs had a HBV/HIV 
co-infection, and 6.6 percent (n=39) of HIV positive 
IDUs were also positive for HBV and HCV. Figure 2 
illustrates the prevalence of HBV infection among 
IDUs with or without HIV and HCV infections.
IDUs who were HIV positive and/or  
co-infected with HCV were more likely to  
engage in risky injection behavior than  
IDUs who were HIV and HCV negative 
HIV/HCV negative IDUs were less likely to have 
practiced risky injection in the last month compared 
to those infected with either or both infections. A 
little more than a third (36.4 percent) had previously 
shared needle/syringes, back/front loaded or split 
drugs, drawn up drugs from common containers, or 
received pre-filled injection, or shared equipment in 
the last month. However, these risky injection prac-
tices were more frequently reported by HCV positive 
male IDUs (62.4 percent) and HIV/HCV co-infected 
IDUs (65.3 percent). 
Program Implications and  
Recommendations
Despite the availability of targeted intervention pro-
grams that recommend HIV testing and counseling 
every six months, the majority of male IDUs did not 
have comprehensive HIV knowledge. Awareness of 
HBV and HCV was even lower. Counseling should 
include information about HBV and HCV preven-
tion. Counselors should assess comprehensive HIV 
knowledge among persons undergoing HIV testing 
at the end of every counseling session.
Hepatitis C prevalence and co-infection with HIV was 
extremely high in this cohort of male IDUs and high 
risk injection practices were more frequent among 
infected IDUs. This has serious implications for 
onward transmission to injecting and sex partners of 
these IDUs. Further, HCV infection has a strong link 
with liver chronicity and hepatocellular carcinoma. 
Thus HCV prevention must be a priority in targeted 
interventions for IDUs. Given the prohibitively high 
cost of HCV treatment and the lack of vaccine for 
HCV, primary prevention such as safer injection 
practices and prevention of drug injection initiation 
must be emphasized. Although targeted intervention 
programs provide sterile needles and syringes and 
many IDUs use this services, this does not neces-
sarily translate into safe behaviors in a sustained 
fashion. HIV prevention programs need to review 
strategies to engineer a long-term behavior change.
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Figure 2  Prevalence of HBV and co-infection with HIV and HCV (n=2,292)
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